Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06127043 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
A Phase 2 study of Ulcerative Colitis, sponsored by AnaptysBio.
- Active
- Registry status
- Phase 2
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT06127043 is a Phase 2 study of Ulcerative Colitis that is active but no longer recruiting, run by AnaptysBio. The registered enrollment target is 132 participants, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06127043, a Phase 2 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by AnaptysBio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rosnilimab
Study Locations (20)
Florida
- AnaptysBio Investigational Site 10-127 - Brooksville
- AnaptysBio Investigational Site 10-106 - Miami
- AnaptysBio Investigational Site 10-109 - Miami Gardens
- AnaptysBio Investigational Site 10-131 - Orlando
- AnaptysBio Investigational Site 10-123 - Orlando
- AnaptysBio Investigational Site 10-125 - Tampa
California
- AnaptysBio Investigational Site 10-117 - Garden Grove
- AnaptysBio Investigational Site 10-112 - Lancaster
- AnaptysBio Investigational Site 10-129 - Lancaster
- AnaptysBio Investigational Site 10-108 - San Jose
Texas
- AnaptysBio Investigational Site 10-104 - Dallas
- AnaptysBio Investigational Site 10-113 - Garland
Arizona
- AnaptysBio Investigational Site 10-115 - Phoenix
Georgia
- AnaptysBio Investigational Site 10-122 - Atlanta
Illinois
- AnaptysBio Investigational Site 10-124 - Oak Lawn
Nevada
- AnaptysBio Investigational Site 10-118 - Las Vegas
New York
- AnaptysBio Investigational Site 10-133 - Utica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06127043
The ClinicalTrials.gov registry entry for NCT06127043 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,056-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (94% lower). The listed sponsor is AnaptysBio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06127043 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06127043 about?
NCT06127043 is a clinical study titled "A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)". ROSETTA STUDY: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe ulcerative colitis (UC)
What is the current status of trial NCT06127043?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 132 participants. The study started on 2023-12-04. Estimated completion is 2026-05.
What conditions does trial NCT06127043 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06127043?
The interventions under investigation include: Placebo (DRUG), Rosnilimab (DRUG).
Who is sponsoring clinical trial NCT06127043?
This trial is sponsored by AnaptysBio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06127043 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.